Summary
Welzel, et al. [1] recently published a randomized controlled trial (RCT) comparing the efficacy of methylprednisolone (MP) with intravenous immunoglobulin (IVIg) for COVID-19 associated pediatric inflammatory multisystem syndrome, also referred to as COVID-19 associated multisystem inflammatory syndrome in children (MIS-C). This study was necessitated by the helplessness associated with the condition, in the face of the COVID pandemic, coupled with the ray of hope offered by these medications, documented through physician experiences and observational studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Welzel T, Atkinson A, Schöbi N, et al. Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multi-centre, randomised trial. Lancet Child Adolesc Health. 2023;7:238–48.
Harthan AA, Nadiger M, McGarvey JS, et al. Early combination therapy with immunoglobulin and steroids is associated with shorter ICU length of stay in multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19: A retrospective cohort analysis from 28 U.S. Hospitals. Pharmacotherapy. 2022;42:529–39.
Funding
None
Author information
Authors and Affiliations
Corresponding author
Additional information
Competing interests
None stated.
Rights and permissions
About this article
Cite this article
Mathew, J.L. Methylprednisolone or Intravenous Immunoglobulin in Children with Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS)?. Indian Pediatr 60, 571–574 (2023). https://doi.org/10.1007/s13312-023-2937-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-023-2937-7